STRO-002 Continues to Show Promise in Phase 1 Trial for Advanced Ovarian Cancer

STRO-002 Continues to Show Promise in Phase 1 Trial for Advanced Ovarian Cancer
STRO-002, Sutro Biopharma’s experimental antibody-drug conjugate, continues to be safe and elicit promising responses in heavily pretreated patients with advanced ovarian cancer, according to the latest data from a Phase 1 clinical trial. Updated interim findings from the ongoing open-label study (NCT03748186) showed that 32% of women who were eligible for response analyses responded to STRO-002, when given at doses of 2.9 mg/kg or higher. “We are encouraged to see meaningful clinical benefit from STRO-002 for patients with advanced platinum-resistant and refractory ovarian cancer. The women on the study are heavily pretreated and have limited treatment options as many have received experimental agents and participated in other clinical trials,” Lainie P. Martin, MD, said in a press release. Martin is a trial investigator and leader of the Gynecology/Oncology Program at the Hospital of the University of Pennsylvania,  “The deepening of responses in patients as well as disease control over time demonstrates STRO-002 to be an important potential treatment option for patients with ovarian cancer,” Martin added. The findings were presented recently by Sutro during a virtual discussion with key opinion leaders. STRO-002 is an antibody-drug conjugate made up of an antibody that specifically binds to folate receptor alpha, a protein found at high levels in most types of ovarian cancer. When the antibody binds to its target, it triggers the release of a toxic compound that destroys cancer cells, while sparing healthy cells. The safety, tolerability, and preliminary efficacy of STRO-002 are being investigated in the Phase 1 trial, which is enrolling heavily pretreated women with recurrent advanced platinum-resistant or refractory ovarian cancer (incl
Subscribe or to access all post and page content.